Literature DB >> 30211262

Data on association of ankle pressure and ankle brachial index of symptomatic and contralateral lower extremities with overall and cardiovascular mortality in patients with lower extremity peripheral artery disease.

Jan-Erik Wickström1, Juha Virtanen1, Mirjami Laivuori2, Juho Jalkanen1, Maarit Venermo2, Harri Hakovirta1.   

Abstract

Data on survival curves for overall survival and freedom from cardiovascular death at different ankle brachial index (ABI) and ankle pressure (AP) are shown separately for symptomatic and contralateral lower limbs in 721 patients with lower extremity peripheral artery disease at up to 7 years follow-up. Cox regression analysis with confounding factors for ABI and AP are also shown. Dates and causes of death were collected from the Finnish national statistics registry.

Entities:  

Year:  2018        PMID: 30211262      PMCID: PMC6129675          DOI: 10.1016/j.dib.2018.08.041

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data Patient cohort consists of 721 patients with symptomatic lower extremity peripheral artery disease Analysis of both symptomatic and contralateral ankle brachial index and ankle pressure in relation to patient outcome Data may be used for assessing the role of pressure measurements with respect to patient outcome

Data

The presented data is acquired from analysis of non-invasive peripheral pressure measurements of patients with clinically symptomatic (Rutherford 2–6) peripheral artery disease [2], [3]. Fig. 1A–D shows Kaplan-Meier curves for freedom from cardiovascular death and overall survival at defined ABI categories for both symptomatic and contralateral extremity. Corresponding Kaplan-Meier curves are presented for ankle pressure in Fig. 2A–D. Cox regression analyses with confounding factors for ABI and AP are presented in Table 1.
Fig. 1

A-D Kaplan-Meier curves showing A) cumulative freedom from cardiovascular death and B) overall survival by defined ABI categories for symptomatic limb. Corresponding Kaplan-Meier curves showing C) cumulative freedom from cardiovascular death and D) overall survival for contralateral limb. Up to 7 years follow-up. Life tables for 0, 20, 40, 60 and 80 months shown in lower part of the panels. Pairwise (Wilcoxon) comparison between groups: A) ABI < 0.25 vs. 0.25–0.89: P < 0.001; vs. 0.9–1.3: P = 0.018; vs. > 1.3: P = 0.665, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.594; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P < 0.001 B) ABI < 0.25 vs. 0.25–0.89: P < 0.001; vs. 0.9–1.3: P = 0.026; vs. > 1.3: P = 0.707, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.561; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P = 0.003 C) ABI < 0.25 vs. 0.25–0.89: P = 0.001; vs. 0.9–1.3: P < 0.001; vs. > 1.3: P = 0.428, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.174; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P < 0.001 D) ABI < 0.25 vs. 0.25–0.89: P = 0.061; vs. 0.9–1.3: P = 0.012; vs. > 1.3: P = 0.817, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.061; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P < 0.001.

Fig. 2

A-D Kaplan-Meier curves showing A) cumulative freedom from cardiovascular death and B) overall survival by defined AP categories for symptomatic limb. Corresponding Kaplan-Meier curves showing C) cumulative freedom from cardiovascular death and D) overall survival for contralateral limb. Up to 7 years follow-up. Life tables for 0, 20, 40, 60 and 80 months shown in lower part of the panels. Pairwise (Wilcoxon) comparison between groups: A) AP (mmHg) < 50 vs. 50–69: P = 0.022; vs. 70–249: P < 0.001; vs. ≥ 250: P = 0.90, AP (mmHg) 50–69 vs. 70–249: P = 0.68; vs. ≥ 250: P = 0.014, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001 B) AP (mmHg) < 50 vs. 50–69: P = 0.123; vs. 70–249: P = 0.001; vs. ≥ 250: P = 0.263, AP (mmHg) 50–69 vs. 70–249: P = 0.20; vs. ≥ 250: P = 0.005, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001 C) AP (mmHg) < 50 vs. 50–69: P = 0.076; vs. 70–249: P < 0.001; vs. ≥ 250: P = 0.995, AP (mmHg) 50–69 vs. 70–249: P = 0.63; vs. ≥ 250: P = 0.008, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001 D) AP (mmHg) < 50 vs. 50–69: P = 0.466; vs. 70–249: P = 0.025; vs. ≥ 250: P = 0.332, AP (mmHg) 50–69 vs. 70–249: P = 0.011; vs. ≥ 250: P = 0.003, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001.

Table 1

Cox regression analysis for ABI (A) and cardiovascular and overall mortality for symptomatic and contralateral limb. Reference ABI 0.90-1.30. B) Corresponding Cox regression analysis for AP (B). Reference AP 70-250 mmHg. Confounding factors forced into Cox regression analysis were chosen according to their significance (P < 0.20) in univariate analysis. CAD: coronary artery disease; HT: hypertension; DM: diabetes, ESRD: end-stage renal disease.

A
HR95% CIP value
CardiovascularABI, symptomatic limb
Age0.9780.965–0.992< 0.01
CAD1.451.09–1.920.01
HT1.270.917–1.760,.15
DM1.290.967–1.730.08
ESRD1.501.01–2.340.04
Statin use0.7850.585–1.050.11
Smoking history0.4740.324–0.694< 0.01
0.90-1.30Reference
0.25-0.891.180.679–2.070.55
< 0.252.311.23–4.370.01
> 1.302.801.45–5.39< 0.01



ABI, contralateral limb
Age0.9840.971–0.9980.02
CAD1.461.10–1.94< 0.01
HT1.280.926–1.770.14
DM1.200.898–1.610.22
ESRD1.581.05–2.370.03
Statin use0.6890.511–0.9290.02
Smoking history0.4940.336–0.725< 0.01
0.90–1.30Reference
0.25–0.891.441.03–2.020.04
< 0.252.891.92–4.340.01
> 1.303.461.63–7.34< 0.01
OverallABI, symptomatic limb
Age0.9780.968–0.988< 0.01
CAD1.170.937–1.480.17
HT1.210.942–1.540.14
DM1.070.852–1.340.56
ESRD1.601.17–2.19< 0.01
Statin use0.7790.620–0.9800.03
Smoking history0.5730.436–0.754< 0.01
0.90–1.30Reference
0.25–0.891.040.690–1.570.85
< 0.251.951.16–3.250.01
> 1.301.971.22–3.20< 0.01



ABI, contralateral limb
Age0.9810.971–0.992< 0.01
CAD1.180.950–1.480.13
HT1.210.945–1.550.13
DM1.030.819–1.290.81
ESRD1.691.22–2.33< 0.01
Statin use0.7010.556–0.885< 0.01
Smoking history0.5790.438–0.763< 0.01
0.90–1.30Reference
0.25–0.891.411.09–1.820.01
< 0.252.201.06–4.570.03
> 1.302.631.91–3.63< 0.01

A-D Kaplan-Meier curves showing A) cumulative freedom from cardiovascular death and B) overall survival by defined ABI categories for symptomatic limb. Corresponding Kaplan-Meier curves showing C) cumulative freedom from cardiovascular death and D) overall survival for contralateral limb. Up to 7 years follow-up. Life tables for 0, 20, 40, 60 and 80 months shown in lower part of the panels. Pairwise (Wilcoxon) comparison between groups: A) ABI < 0.25 vs. 0.25–0.89: P < 0.001; vs. 0.9–1.3: P = 0.018; vs. > 1.3: P = 0.665, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.594; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P < 0.001 B) ABI < 0.25 vs. 0.25–0.89: P < 0.001; vs. 0.9–1.3: P = 0.026; vs. > 1.3: P = 0.707, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.561; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P = 0.003 C) ABI < 0.25 vs. 0.25–0.89: P = 0.001; vs. 0.9–1.3: P < 0.001; vs. > 1.3: P = 0.428, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.174; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P < 0.001 D) ABI < 0.25 vs. 0.25–0.89: P = 0.061; vs. 0.9–1.3: P = 0.012; vs. > 1.3: P = 0.817, ABI 0.25–0.89 vs. 0.9–1.3: P = 0.061; vs. > 1.3: P < 0.001, ABI 0.9–1.3 vs. > 1.3: P < 0.001. A-D Kaplan-Meier curves showing A) cumulative freedom from cardiovascular death and B) overall survival by defined AP categories for symptomatic limb. Corresponding Kaplan-Meier curves showing C) cumulative freedom from cardiovascular death and D) overall survival for contralateral limb. Up to 7 years follow-up. Life tables for 0, 20, 40, 60 and 80 months shown in lower part of the panels. Pairwise (Wilcoxon) comparison between groups: A) AP (mmHg) < 50 vs. 50–69: P = 0.022; vs. 70–249: P < 0.001; vs. ≥ 250: P = 0.90, AP (mmHg) 50–69 vs. 70–249: P = 0.68; vs. ≥ 250: P = 0.014, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001 B) AP (mmHg) < 50 vs. 50–69: P = 0.123; vs. 70–249: P = 0.001; vs. ≥ 250: P = 0.263, AP (mmHg) 50–69 vs. 70–249: P = 0.20; vs. ≥ 250: P = 0.005, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001 C) AP (mmHg) < 50 vs. 50–69: P = 0.076; vs. 70–249: P < 0.001; vs. ≥ 250: P = 0.995, AP (mmHg) 50–69 vs. 70–249: P = 0.63; vs. ≥ 250: P = 0.008, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001 D) AP (mmHg) < 50 vs. 50–69: P = 0.466; vs. 70–249: P = 0.025; vs. ≥ 250: P = 0.332, AP (mmHg) 50–69 vs. 70–249: P = 0.011; vs. ≥ 250: P = 0.003, AP (mmHg) 70–249 vs. ≥ 250: P < 0.001. Cox regression analysis for ABI (A) and cardiovascular and overall mortality for symptomatic and contralateral limb. Reference ABI 0.90-1.30. B) Corresponding Cox regression analysis for AP (B). Reference AP 70-250 mmHg. Confounding factors forced into Cox regression analysis were chosen according to their significance (P < 0.20) in univariate analysis. CAD: coronary artery disease; HT: hypertension; DM: diabetes, ESRD: end-stage renal disease.

Experimental design, materials and methods

Present data consists of peripheral pressure measurements in 721 symptomatic PAD patients admitted to the Department of Vascular Surgery at Turku University Hospital for digital subtraction angiography between January 2009 and August 2011. Dates and causes of death were collected from the Finnish national statistics registry at the end of the study period. Baseline demographics were collected from electronic patient files.

Non-invasive peripheral pressure measurements

Standardised peripheral pressure measurements were obtained in a vascular laboratory at Turku University Hospital. A Nicolet VasoGuard (Nicolet Vascular inc., Madison, WI, USA) photopletysmography (PPG) device was used for all measurements. Measurements were obtained with patients in a supine position with feet at heart level. When stable signals were obtained, brachial and ankle cuffs were inflated until disappearance of the PPG signal. Brachial and ankle pressures were determined by gradual deflation of the cuffs to the moment of reappearance of a pulsatile signal.

Statistical analysis

All statistical analyses were performed with SPSS version 22 (IBM, Armonk, NY, USA). Survival was assessed by Kaplan-Meier curves and Log-rank statistics. A Cox regression analysis was performed to assess the final predictive value of factors affecting survival. Factors with P < 0.2 in Cox univariate analysis were forced into a Cox proportional hazard model to assess the risk of death.
Subject areaMedicine
More specific subject areaVascular surgery
Type of dataTables, figures
How data was acquiredRetrospective analysis of patient files
Data formatRaw, analyzed
Experimental factorsAnkle pressure, ankle brachial index
Experimental featuresRetrospective analysis of overall mortality and freedom from cardiovascular death
Data source locationTurku University Hospital, Turku, Finland
Data accessibilityData is with this article
Related research articleWickström et al. [1]
  2 in total

1.  Recommended standards for reports dealing with lower extremity ischemia: revised version.

Authors:  R B Rutherford; J D Baker; C Ernst; K W Johnston; J M Porter; S Ahn; D N Jones
Journal:  J Vasc Surg       Date:  1997-09       Impact factor: 4.268

Review 2.  Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).

Authors:  Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais; Petr Widimsky; Philippe Kolh; Stefan Agewall; Héctor Bueno; Antonio Coca; Gert J De Borst; Victoria Delgado; Florian Dick; Cetin Erol; Marc Ferrini; Stavros Kakkos; Hugo A Katus; Juhani Knuuti; Jes Lindholt; Heinrich Mattle; Piotr Pieniazek; Massimo Francesco Piepoli; Dierk Scheinert; Horst Sievert; Iain Simpson; Jakub Sulzenko; Juan Tamargo; Lale Tokgozoglu; Adam Torbicki; Nikolaos Tsakountakis; José Tuñón; Melina Vega de Ceniga; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur J Vasc Endovasc Surg       Date:  2017-08-26       Impact factor: 7.069

  2 in total
  2 in total

1.  The Cardiovascular-Mortality-Based Estimate for Normal Range of the Ankle-Brachial Index (ABI).

Authors:  Essi Peltonen; Mirjami Laivuori; Damir Vakhitov; Päivi Korhonen; Maarit Venermo; Harri Hakovirta
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-05

2.  Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.

Authors:  Erkki Soini; Outi Virtanen; Saku Väätäinen; Jean-Baptiste Briere; Kevin Bowrin; Aurelie Millier
Journal:  Adv Ther       Date:  2020-06-09       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.